Open AccessSHMT1 C1420T polymorphism contributes to the risk of non‐Hodgkin lymphoma: evidence from 7309 patients
Author(s) -
Wang YiWei,
Zhang ShaoDan,
Xue WenJi,
Zhu MeiLing,
Zheng LeiZhen
Publication year - 2015
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1186/s40880-015-0065-z
Subject(s) - odds ratio , medicine , confidence interval , oncology , meta analysis , lymphoma , allele , methylenetetrahydrofolate reductase , endocrinology , biology , gastroenterology , genetics , gene
Background Serine hydroxymethyltransferase 1 (SHMT1) is a key enzyme in the folate metabolic pathway that plays an important role in biosynthesis by providing one carbon unit. SHMT1 C1420T may lead to the abnormal biosynthesis involved in DNA synthesis and methylation, and it may eventually increase cancer susceptibility. Many epidemiologic studies have explored the association between C1420T polymorphism and the risk of non‐Hodgkin lymphoma (NHL), but the results have been contradictory. Therefore, we performed this meta‐analysis to evaluate the relationship. Methods The meta‐analyses were conducted to evaluate the effect of SHMT1 C1420T polymorphism on NHL risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association. Results Eight studies encompassing 3232 cases and 4077 controls were included. A statistically significant association was found between SHMT1 C1420T polymorphism and NHL risk under the allelic comparison (T vs. C: OR = 1.09, 95% CI 1.01–1.17); a borderline association was found between SHMT1 C1420T polymorphism and NHL risk under the homozygote model (TT vs. CC: OR = 1.18, 95% CI 1.00–1.39) and the dominant model (CT+TT vs. CC: OR = 1.10, 95% CI 1.00–1.21). Conclusion SHMT1 C1420T polymorphism may be associated with NHL risk, which needs to be validated in large, prospective studies.